Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

223 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Focus on melanoma.
Houghton AN, Polsky D. Houghton AN, et al. Cancer Cell. 2002 Oct;2(4):275-8. doi: 10.1016/s1535-6108(02)00161-7. Cancer Cell. 2002. PMID: 12398891 Review. No abstract available.
Frequent p16-independent inactivation of p14ARF in human melanoma.
Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, Randerson-Moor JA, Houghton A, Busam K, Timothy Bishop D, Bastian BC, Newton-Bishop JA, Polsky D. Freedberg DE, et al. J Natl Cancer Inst. 2008 Jun 4;100(11):784-95. doi: 10.1093/jnci/djn157. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505964 Free PMC article.
A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB, Patel A, Ishill N, Hanlon C, Brady MS, Halpern AC, Houghton A, Coit DG. Neuman HB, et al. Ann Surg Oncol. 2008 Jul;15(7):2034-41. doi: 10.1245/s10434-008-9915-0. Epub 2008 May 9. Ann Surg Oncol. 2008. PMID: 18465172
Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression.
Cotignola J, Roy P, Patel A, Ishill N, Shah S, Houghton A, Coit D, Halpern A, Busam K, Berwick M, Orlow I. Cotignola J, et al. J Negat Results Biomed. 2007 Oct 24;6:9. doi: 10.1186/1477-5751-6-9. J Negat Results Biomed. 2007. PMID: 17958893 Free PMC article.
HDM2 protein overexpression and prognosis in primary malignant melanoma.
Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C, Osman I. Polsky D, et al. J Natl Cancer Inst. 2002 Dec 4;94(23):1803-6. doi: 10.1093/jnci/94.23.1803. J Natl Cancer Inst. 2002. PMID: 12464652
Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.
Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M, Orlow I. Cotignola J, et al. BMC Med Genet. 2007 Mar 8;8:10. doi: 10.1186/1471-2350-8-10. BMC Med Genet. 2007. PMID: 17346338 Free PMC article.
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J. Soiffer RJ, et al. Among authors: houghton an. Clin Cancer Res. 1997 Jan;3(1):17-24. Clin Cancer Res. 1997. PMID: 9815532 Clinical Trial.
A melanosomal membrane protein is a cell surface target for melanoma therapy.
Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. Takechi Y, et al. Among authors: houghton an. Clin Cancer Res. 1996 Nov;2(11):1837-42. Clin Cancer Res. 1996. PMID: 9816138
Times are a changin': the era of peptide immunization begins.
Houghton AN. Houghton AN. Cancer J Sci Am. 1997 Jan-Feb;3(1):4-5. Cancer J Sci Am. 1997. PMID: 9072307 No abstract available.
Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells.
Spielholz C, Golde DW, Houghton AN, Nualart F, Vera JC. Spielholz C, et al. Among authors: houghton an. Cancer Res. 1997 Jun 15;57(12):2529-37. Cancer Res. 1997. PMID: 9192836
223 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback